MSD Veterinary Manual
Important: The authors, reviewers, and editors of this material have made extensive efforts to ensure that treatments, drugs, and discussions about medical practice are accurate and conform to the standards accepted at the time of publication. However, constant changes in information resulting from continuing research and clinical experience, reasonable differences in opinions among authorities, unique aspects of individual clinical situations, and the possibility of human error in preparing such an extensive text mean that other sources of medical information may differ from the information on this site.
The information on this site is not intended to be professional advice and is not intended to replace personal consultation with a qualified veterinarian, pharmacist, or other health care professional. The reader should not disregard medical advice or delay seeking it because of something found on this site. Content in the Manuals reflects medical practice and information in the United States. Outside of the United States, clinical guidelines, practice standards, and professional opinion may differ and the reader is advised to also consult local medical sources.
Please note, not all content that is available in English is available in every language. Common Veterinary Topics. Videos Figures Images Quizzes. Thousands of topics in all veterinary fields. Information that is clear and easy to understand on thousands of veterinary topics. Free, and always will be. The Merck Manuals are offered as a free public service to the general public and veterinary professionals.
Authored by hundreds of top veterinary experts. Photos, Videos, Animations and more! Thousands of photos and illustrations, hundreds of animations and videos, quizzes to test your knowledge, veterinary news, social media. Featured content.
Videos View All. Foal with congenital cleft palate nursing. Notice milk from the nares. Goat with heartwater showing respiratory distress. Case studies View All. Especially nowadays when so many students seem to be so perfect — they have a 4. Chocolate Toxicity Calculator. Quick Links. Test your knowledge View All. Racing Thoroughbreds perform high-intensity exercise for short durations and are at risk of developing exertional heat illness.
Which of the following is NOT considered a risk factor? Add to Any Platform.
Featured content. Videos View All. Foal with congenital cleft palate nursing. Notice milk from the nares. Goat with heartwater showing respiratory distress.
Case studies View All. Especially nowadays when so many students seem to be so perfect — they have a 4. Chocolate Toxicity Calculator.
Quick Links. However, some elements pointed at a narrower geographic market definition than the EEA. Indeed, if some important customers negotiate contracts at European or even global level,58 the market investigation indicated that many customers negotiate their purchasing contracts at regional or national levels59 and suppliers 53 See reply of a customer to question 18 — Phase 1 questionnaire to customers.
See also replies to question 29 — Phase 1 questionnaire to customers. Competition assessment Merck and Sigma are the two main suppliers of laboratory chemicals in the EEA. While they are present and widely recognised players across the whole spectrum of laboratory chemicals, such presence is more significant and has distinctive features in the markets for catalogue solvents and inorganics in the EEA.
These markets are assessed in Section IV. Therefore, these markets will not be discussed further in the Decision. Solvents and inorganics This section will first present a general description of the main competitive characteristics which are common to solvents and inorganics markets IV. Then, the markets structure for catalogue solvents and catalogue inorganics will be analysed IV.
General competitive features of catalogue solvents and inorganics markets IV. Reliability of market share data From the outset it should be noted that the market share data provided by the Notifying Party on these markets cannot be fully reliable in light of methodological challenges and the absence of public sources.
While the manufacturing of the basic chemical may be a commoditized process, selling laboratory chemicals requires a highly specialized business model. Because these products are used in standardized testing protocols, where high precision and accuracy are required, it is of utmost importance that customers are sure that the chemicals they purchase are compliant with the exact specifications prescribed by the protocol.
Indeed, any minimal difference in the chemical composition or purity of a solvent or an inorganic may affect the behaviour of chemical substances handled in a laboratory and thus testing results. This enables top quality producers, such as Merck and Sigma, to command price premiums.
This quality is generally perceived in the market place through brands. Breadth of the product portfolio Aside from product quality and brands, another important parameter of competition is the breadth of the product portfolio. This is explained by the fact that there is a wide variety of solvents and inorganics purchased by the customers and used in testing and quality control protocols.
On the other hand, suppliers typically strive to supply the whole spectrum, often under the same brand. Some respondents expressly indicated 77 See reply of a customer to questions — Phase I questionnaire to customers.
Channels to the market Customers of solvents and inorganics are typically companies and other institutions, such as academic institutions, which have a research facility or a laboratory where they perform testing or quality control of their products.
Sales are therefore scattered across a wide number of customers, which often need small quantities of several products from the portfolio. In order to be able to compete on this market, it is thus essential to own or have access to an efficient distribution system, also enabling a quick time of delivery of often hazardous or temperature sensitive material.
These findings are in line with the market analysis of the Parties as outlined in their internal documents. This is clearly a 86 Agreed minutes of the call with [Company Name], Barriers to entry to the catalogue solvents and inorganics markets Despite the leading position and closeness of competition of Merck and Sigma in the whole EEA, the Notifying Party argues that, in any event, anticompetitive effects could be excluded since barriers to entry in the markets for the supply of catalogue solvents and inorganics are low.
In this context the Notifying Party reiterates that suppliers of catalogue solvents and inorganics which are often purchasing raw chemicals in bulk from the large chemical manufacturers provide limited added value services, such as quality assurance and control, or purification, to the product originally produced by bulk manufacturers. Contracts with third party manufacturers would be widely available and raw materials producers, such as Ineos, Akzo Nobel and BASF, which are already present in respect to bulk sales, would be capable of entering the catalogue market quickly if a hypothetical price increase made such entry attractive.
Finally, customers would easily switch among brands given the identity of the products purchased. In line with the general features of the market exposed above, the barriers to entry to these markets are considerable.
This analysis is also shared by many customers. The utilization rate of a plant would typically be low and sales of solvents and inorganics in small quantities appear to be a viable activity only if a supplier can propose a wide portfolio of chemicals to an important customer base.
In this respect, it is crucial for any party willing to enter this market to be able to offer a sufficiently broad product portfolio across the spectrum of solvents and inorganics. This analysis was confirmed by market participants Nobody knows which item sells well in advance, so many items must be stored in each area to be delivered quickly.
In particular, as to inorganics, Sigma had a long patent protection on first generation Karl Fisher titration solutions, from to On , Sigma was granted a new patent protection for a second generation Karl Fisher titration solution, which will expire in Bulk manufacturers explained that they would not be willing or able to start being active in the laboratory chemicals market post-merger. Customers would not trust the brand.
Besides these significant barriers to switching, barriers to entry are also high and would make it unlikely for other players, including large bulk chemical companies, to enter or expand on this market. Organics and other laboratory chemicals According to data provided by the Notifying Party, the Transaction results in 9 horizontally affected markets or market segments in the supply of organics and other laboratory chemicals reference materials, analytical chromatography, industrial microbiology in the EEA.
In those instances where the products concerned are materially subject to IP rights, as it is the case for instance for HPLC Columns, the parties do not have a significant share of the market. Product market The Notifying Party submits that the relevant product market for distribution comprises the distribution of all laboratory and life science products. Distributors are able and do offer a range of products including laboratory chemicals as well as other laboratory consumables and life science products.
Moreover, the same product market would comprise both traditional distributors and on-line distributors, as despite the different features of these channels, on-line distributors offer a range of products that is equivalent to that offered by traditional distributors. One distributor also generically indicated reference standards as an area of strength.
Geographic market The Notifying Party submits that there is a trend towards cross-border distribution of laboratory and life science products, although it acknowledges that the distribution market could be divided across national lines.
Competition assessment IV. As the Parties do not have a significant degree of market power on the downstream market, customer foreclosure is unlikely to be a concern in the case at hand. Input foreclosure As evidenced in sections IV. Should the merged entity be deemed to have a significant degree of market power regarding the upstream markets, it could potentially have an ability and incentive to leverage influence on the conditions of competition in these markets on prices and supply conditions in the downstream market for the distribution of laboratory and life science products.
Nonetheless, these markets will only represent a fraction of the entire laboratory and life science portfolio of any given distributor, thereby mitigating the impact of any possible input foreclosure from the combined entity. Furthermore, the full overlap in relation to solvents and inorganics sold in the EEA will be removed by the Commitments offered by the Parties, and thus any vertical concerns will also be mitigated.
Indeed, sales through distributors are a complementary sales channel to direct sales, and allow manufacturers of laboratory chemicals to expand their geographic and customer footprint.
Given the highly fragmented customer base in relation to laboratory chemicals, suppliers always have an incentive to rely on a number of distributors to achieve as wide sales of their products as possible. This is also illustrated by the strategy of Thermo-Fisher, a key vertically integrated competitor of the Parties, which besides its own distribution channels also sells a number of its products through a global distributor VWR.
Conclusion In view of the information provided by the Parties, and of the results of the market investigation, the Commission therefore concludes that the proposed Transaction is unlikely to significantly impede competition in relation to the market for the distribution of laboratory and life science products.
Framework for the assessment of the Commitments Where a concentration raises serious doubts as regards its compatibility with the internal market, the Parties may undertake to modify the concentration so as to remove the grounds for the serious doubts identified by the Commission. Concerning the form of acceptable commitments, the Merger Regulation gives discretion to the Commission as long as the commitments meet the requisite standard.
Structural commitments will meet the conditions set out above only in so far as the Commission is able to conclude with the requisite degree of certainty, at the time of its Decision, that it will be possible to implement them and that it will be likely that the new commercial structures resulting from them will be sufficiently workable and lasting to ensure that effective competition will be maintained.
The Commission market tested the Initial Commitments in order to assess whether they are sufficient and suitable to remedy serious doubts identified in the catalogue solvents and inorganics markets.
These Final Commitments are annexed to this Decision and form an integral part thereof. The license is followed by an additional […]black-out period during which neither Merck nor the Purchaser are allowed to sell solvents and inorganics under the Sigma-Aldrich brand in the EEA; d. Results of the market test and assessment of the Initial Commitments The market test was launched on 22 May and sought to assess mainly the scope and effectiveness of the Initial Commitments, their viability, the attractiveness of the Divestment Business as well as the suitability of the Purchaser criteria.
Specifically, the following key issues were raised: a. Final Commitments The Parties were informed of the shortcomings identified during the market test within a framework of a State of play meeting held on 2 June and submitted a final text of Commitments addressing the issues on 11 June Overall assessment of the Final Commitments The Commission analysed the suitability of the Final Commitments to remedy the serious doubts identified in relation to catalogue solvents and inorganics markets in the EEA.
To this end, the Commission assessed whether the scope of the Commitments is sufficient and suitable to address the competition concerns identified and the nature of the industry, whether the Divestment Business is viable and the Commitments are likely to be effective in practice and whether the Commitments can be easily implemented and, finally, whether the Divestment Business is attractive for purchasers.
Scope of the Final Commitments and their suitability to remove the identified concerns As explained in this Decision, the significant impediments to effective competition stemming from this case reside in the combination of the most extensive product portfolios, the strongest brands and the most effective channels to the market in the area of solvents and inorganics in the EEA, in markets characterised by significant barriers to switching and significant barriers to entry.
Specifically, it contains manufacturing assets Sigma used in Seelze pursuant to the agreements with Honeywell, all important brands under which solvents and inorganics are sold in the EEA, and solutions for bringing the product to the market irrespective of the nature of the Purchaser. Indeed, even if the Purchaser were not to have any pre-existing sales capability, the Final Commitments would allow it to be immediately present in the market […].
This, on the one hand, mitigates any risk of brand confusion and enhances chances for a long-term viability of the Divestment Business and, on the other hand, enlarges the scope of the Divestment Business beyond the EEA in relation to the main brand, and in particular the one under which the signature Karl Fisher titration solutions and many other premium quality solvents and inorganics are successfully sold worldwide.
In this respect, the option to acquire further equipment from Steinheim, Buchs and other locations where solvents and inorganics sold in the EEA are currently manufactured by Sigma further enhances the production capabilities of the Divestment Business.
It does not include only assets but also critical elements to make a player successful in the solvents and inorganics markets in the EEA, which are a well-known brand, a wide portfolio of products, including high margin inorganics such as Karl Fisher titration solutions, various key customers information and the channels to the market. The product portfolio of solvents and inorganics under the Divestment Business is sufficiently broad to ensure viability as divested solvents and inorganics cover a wide spectrum of laboratory and inorganics, including best-in-class Sigma products such as Karl Fisher titration solutions.
Given the small size of the sales associated with these products, the viability of the Divestment Business is unlikely to be affected. This further enhances the viability of the Divestment Business if operated by a suitable Purchaser. In addition, the transfer of the Fluka related know-how will foster customer retention as customers will have to turn to the Purchaser to obtain these products.
Indeed, the rebranding and black-out periods in relation to the Sigma Aldrich branded products will allow a suitable Purchaser for sufficient time to establish itself in the market with a new brand and develop customer relationships.
In light of this additional extension, the Commission takes the view that co-branding is not necessary. Furthermore, as solvents and inorganics are very different products from other laboratory chemicals, and often sold under different trades names, the final scope of the Divestment Business would not affect the success of the re-branding.
The transfer of […] further enhance the capacity of a suitable Purchaser to reach a fragmented customer base all over the EEA. Overall, the Divestment Business is therefore viable and can be run profitably by a suitable Purchaser. It follows the Commitments are likely to be effective in practice. Ability of the Final Commitments to be implemented in practice Given that the core of the manufacturing assets are located in Seelze which is exploited by Sigma and Honeywell pursuant to a set of agreements […].
Thus, the Commission will approve the Purchaser only if it has assurances that the Purchaser […]. Attractiveness of the package for Purchasers The attractiveness of the Divestment Business was evidenced by the number of potentially interested purchasers, including in particular large competitors of the Parties in the life science area already supplying laboratory chemicals.
Conclusion on Final Commitments For the reasons outlined above, and in view of the results of the market test and the ensuing improvements to the Commitments, the Commission considers the Final Commitments to be sufficient in scope and suitable to eliminate the serious doubts as to the compatibility of the Transaction with the internal market in relation to catalogue solvents and inorganics markets in the EEA.
Where the undertakings concerned commit a breach of an obligation, the Commission may revoke the clearance decision in accordance with Article 8 6 of the Merger Regulation. The undertakings concerned may also be subject to fines and periodic penalty payments under Articles 14 2 and 15 1 of the Merger Regulation. The full text of the final Commitments forms an integral part to this Decision. Section A. Definitions 1. Assets: the assets that contribute to the current operation or are necessary to ensure the viability and competitiveness of the Divestment Business as indicated in Section B, paragraph 2 and described more in detail in the Schedule.
Closing: the transfer of the legal title to the Divestment Business to the Purchaser. Confidential Information: any business secrets, know-how, commercial information, or any other information of a proprietary nature that is not in the public domain. Divestment Business: the business or businesses as defined in Section B and in the Schedule which the Parties commit to divest.
Effective Date: the date of adoption of the Decision. Hold Separate Manager: the person appointed by Merck for the Divestment Business to manage the day-to-day business under the supervision of the Monitoring Trustee. Key Personnel: all personnel necessary to maintain the viability and competitiveness of the Divestment Business, as listed in the Schedule, including the Hold Separate Manager.
Personnel: all staff currently employed by the Divestment Business, including staff seconded to the Divestment Business as well as additional personnel listed in the Schedule. Purchaser: the entity approved by the Commission as acquirer of the Divestment Business in accordance with the criteria set out in Section D.
Purchaser Criteria: the criteria laid down in paragraph 17 of these Commitments that the Purchaser must fulfil in order to be approved by the Commission.
Schedule: the schedule to these Commitments describing more in detail the Divestment Business. The commitment to divest and the Divestment Business Commitment to divest 2. In order to maintain effective competition, the Parties commit to divest, or procure the divestiture of the Divestment Business by the end of the Trustee Divestiture Period as a going concern to a purchaser and on terms of sale approved by the Commission in accordance with the procedure described in paragraph 18 of these Commitments.
To carry out the divestiture, the Parties commit to find a purchaser and to enter into a final binding sale and purchase agreement for the sale of the Divestment Business within the First Divestiture Period.
If the Parties have not entered into such an agreement at the end of the First Divestiture Period, the Parties shall grant the Divestiture Trustee an exclusive mandate to sell the Divestment Business in accordance with the procedure described in paragraph 30 in the Trustee Divestiture Period. The proposed concentration shall not be implemented before the Parties or the Divestiture Trustee has entered into a final binding sale and purchase agreement for the sale of the Divestment Business and the Commission has approved the purchaser and the terms of sale in accordance with paragraph The Parties shall be deemed to have complied with this commitment if: a by the end of the Trustee Divestiture Period, the Parties or the Divestiture Trustee have entered into a final binding sale and purchase agreement and the Commission approves the proposed purchaser and the terms of sale as being consistent with the Commitments in accordance with the procedure described in paragraph 18; b the Closing of the sale of the Divestment Business to the Purchaser takes place within the Closing Period; and c the transfer of assets and personnel specified in paragraphs of the Schedule has been effected, the access obligations as specified in paragraph 33 of the Schedule have been complied with and customer information as specified in paragraph 32 has been transferred.
In order to maintain the structural effect of the Commitments, the Notifying Party shall, for a period of 10 years after Closing, not acquire, whether directly or indirectly, the possibility of exercising influence as defined in paragraph 43 of the Remedies Notice, footnote 3 over the whole or part of the Divestment Business, unless, following the submission of a reasoned request from the Notifying Party showing good cause and accompanied by a report from the Monitoring Trustee as provided in paragraph of these Commitments , the Commission finds that the structure of the market has changed to such an extent that the absence of influence over the Divestment Business is no longer necessary to render the proposed concentration compatible with the internal market.
The Divestment Business consists of the business detailed in the Schedule which forms an integral part of the Commitments. The Divestment Business, described in more detail in the Schedule, includes all assets and staff that contribute to the current operation or are necessary to ensure the viability and competitiveness of the Divestment Business, in particular: a all tangible and intangible assets including rights in intellectual property ; b all licences, permits and authorisations issued by any governmental organisation for the benefit of the Divestment Business; c all contracts, leases, commitments and customer orders of the Divestment Business; all customer, credit and other records of the Divestment Business; and d the Personnel.
Strict firewall procedures will be adopted so as to ensure that any competitively sensitive information related to, or arising from the transitional arrangements described in the Schedule will not be shared with, or passed on to, anyone, other than for the purpose of the implementation of the Commitments. Section C. Related commitments Preservation of viability, marketability and competitiveness 9.
From the Effective Date until Closing, the Parties shall preserve or procure the preservation of the economic viability, marketability and competitiveness of the Divestment Business, in accordance with good business practice, and shall minimise as far as possible any risk of loss of competitive potential of the Divestment Business. In particular the Parties undertake: a not to carry out any action that might have a significant adverse impact on the value, management or competitiveness of the Divestment Business or that might alter the nature and scope of activity, or the industrial or commercial strategy or the investment policy of the Divestment Business; b to make available, or procure to make available, sufficient resources for the development of the Divestment Business, on the basis and continuation of the existing business plans; c to take all reasonable steps, or procure that all reasonable steps are being taken, including appropriate incentive schemes based on industry practice , to encourage all 5 Key Personnel to remain with the Divestment Business, and not to solicit or move any Personnel to the retained business or Merck.
Where, nevertheless, individual members of the Key Personnel exceptionally leave the Divestment Business, the Parties shall provide a reasoned proposal to replace the person or persons concerned to the Commission and the Monitoring Trustee. The Parties must be able to demonstrate to the Commission that the replacement is well suited to carry out the functions exercised by those individual members of the Key Personnel.
The replacement shall take place under the supervision of the Monitoring Trustee, who shall report to the Commission.
Hold-separate obligations Provides concise, bulleted information focused on the most important facts needed when treating a poisoned cat or dog Carefully organized for ease of use in an emergency, with important toxicants arranged alphabetically within categories Details clinically relevant information on the most common toxicants encountered by small animals Presents a wealth of color photographs to aid in plant identification Includes 14 new topics to this edition covering cyclosporine A, sleep aids, tacrolimus, bath salts, synthetic marijuana, poisonous lizards, imidacloprid, spring bulbs, and sodium monofluoroacetate.
Color your way to a complete mastery of veterinary anatomy with Veterinary Anatomy Coloring Book, 2nd Edition. Approximately easy-to-color illustrations and corresponding anatomical descriptions guide you through the head, neck, back, thorax, abdomen, extremities, reproductive organs, and many more body parts of dogs, cats, horses, pigs, cows, goats, and birds.
Plus, a new section on exotics takes you through the anatomy of ferrets, rodents, rabbits, snakes, and lizards to ensure you are well versed in all potential household pets. With this vivid change-of-pace study tool, you have the freedom to master veterinary anatomy in a fun and memorable way. Over easy-to-color illustrations created by expert medical illustrators shows anatomy in detail and makes it easy to identify specific structures for an entertaining way to learn veterinary anatomy.
Regional section organization the head and ventral neck; neck, back, and vertebral column; thorax; abdomen; pelvis and reproductive organs; forelimb; and hindlimb allows students to easily compare the anatomy of multiple species.
Numbered lead lines clearly identify structures to be colored and correspond to a numbered list beneath the illustration. Section on exotics covers the anatomy of ferrets, rodents, rabbits, snakes and lizards in addition to the anatomy of dogs, cats, horses, pigs, cows, goats, and birds. Recognize and treat the parasites seen in veterinary practice! Diagnostic Parasitology for Veterinary Technicians, 5th Edition features clear and concise discussions of the most commonly encountered internal and external parasites.
Chapters are organized by parasite group — including nematodes, cestodes, trematodes, protozoans, arthropods, and leeches — and include a detailed description of the group, with special emphasis on morphology, life cycle, and important parasites. Then in each chapter, material is conveniently organized by host species: dogs, cats, horses, ruminants, swine, birds, lab animals, fish, and reptiles.
Written by noted educators Charles Hendrix and Ed Robinson, this full-color, spiral-bound book provides the knowledge that veterinary technicians need to collect samples, perform lab procedures, and communicate with clients and other members of the veterinary team.
Clear, concise coverage simplifies information on the most commonly encountered internal and external parasites, preparing you for credentialing exams and the veterinary clinic. More than full-color photos show exactly what ova, adult parasites, and parasitic diseases look like, so you can identify them more easily when viewing lab samples. Step-by-step guidelines in the Laboratory Procedures chapter describe how to gather samples and how to perform the laboratory techniques used in identifying parasites.
Emphasis on the zoonotic potential of parasites helps you alert clients and other health care workers to the significance of zoonotic parasites and shows ways in which you can prevent transmission of a zoonotic parasite, condition, or syndrome from animals to humans. Logical chapter organization follows the sequence of parasitology classes, beginning with a basic overview of external parasites, internal parasites, and nematodes, followed by chapters that go into detail of the parasites by host species.
An appendix lists the parasites of each species and shows their location in the text, making information easy to find. Heartworm section helps you recognize and treat heartworms with an in-depth discussion of the performance and interpretation of diagnostic tests for this major parasite. Summary tables show how to categorize parasites, and include such categories as body systems affected, taxonomic grouping, host species, and location in host. Table of parasites at the front of the book is arranged by host species and includes page numbers for cross-reference throughout the book.
Vet Tech Threads design makes learning easier with chapter outlines, chapter objectives, key terms, and Technician Notes in every chapter. Chapter on terminology familiarizes you with the basic language and classification scheme of parasitology for more effective communication with clients and colleagues.
Flash cards on the Evolve companion website help you learn and memorize key facts about the major parasites, including audio pronunciations. Now in paperback—the most comprehensive home health reference bestseller Millions of people around the world have relied on The Merck Manual Home Health Handbook for quick access to authoritative, accessible health information.
Written by more than internationally respected medical experts, this comprehensive medical resource features extensive, up-to-date coverage of health care for newborns, the elderly, and everyone in between. Dentistry is a relatively new and expanding area for vets. For many years it has been overlooked or inadequately taught at veterinary colleges, leaving students and vets with little or no training in this discipline. Now the interest in this area has increased and dentistry has become an important part of everyday veterinary practice.
Designed to be a ‘how-to-do’ book, this practical manual guides the reader through all the routine dentistry procedures carried out in general practices. With over colour pictures and special sections on practical tips and trouble-shooting, Small Animal Dentistry is an essential easy-access reference tool for veterinary students and veterinary practitioners alike. Sheep Medicine, Second Edition describes key sheep diseases encountered in general practice along with their diagnoses, treatment, prognoses, control, and, where appropriate, post-mortem features.
The book is divided into chapters covering each body system. Each chapter of this completely revised and updated book opens with a recommended approach t.
Boxer TTL S.C. (en adelante Boxer) con domicilio ubicado en: calle Manuel E. Izaguirre 19, departamento 502, piso 5, Col. Ciudad Satelite Municipio Nucalpan de Juarez, C.P. 53100, Estado de México, en términos de la Ley Federal de Protección de Datos Personales en Posesión de los Particulares (LFPDPPP) del Reglamento de la Ley Federal de Protección de Datos Personales en Posesión de los Particulares (Reglamento), y de los propios Lineamientos del Aviso de privacidad (Lineamientos), este acto notifica a los titulares de los datos personales que posee, la forma y los términos en los que sus datos serán tratados.
El tratamiento de datos personales del titular, tales como: nombre, correo electrónico, teléfono, código postal, género y edad que obren en poder de Boxer, tendrán como finalidades necesarias: la validación de recepción de promociones de Boxer.
Como finalidades secundarias del tratamiento de datos se encuentran:
Boxer de ninguna forma comercializará con sus datos personales en actividades distintas a las señaladas en las finalidades del presente Aviso de Privacidad.
Los datos personales en poder de Boxer son recabados de manera licita e informada y podrán ser transferidos a cualquier tercero con los que Boxer tenga o llegare a tener una relación jurídica, en caso de que así lo estime necesario, para ello se hará del conocimiento del tercero que los trate, las finalidades con las que fueron obtenidos y por lo tanto con las que los podrá usar y/o tratar, procurando su confidencialidad, seguridad física y el establecimiento de procedimientos a seguir en caso de vulneraciones. Aquellos datos personales que obtenga Boxer a través de sus Clientes (Usuarios), de terceros o de fuentes de acceso público, serán tratados con la misma finalidad con la que fueron recabados por el responsable original y con alguna de las finalidades descritas en el presente aviso de privacidad.
Boxer responde a cualquier autoridad de manera enunciativa mas no limitativa: financiera, judicial, fiscal, penal, administrativa, por lo cual, en caso de requerimientos de dichas autoridades podrá transferir los datos personales.
Para realizar este tipo de transferencias de datos no se requiere de su consentimiento por estar permitidas en términos de la LFPDPPP.
Boxer mantendrá en su poder los datos personales a los que se refiere el presente Aviso de Privacidad, hasta por un periodo de al menos 10 (diez) años, o durante el tiempo que la relación jurídica entre el Titular de los Datos y Boxer, ya sea directa o indirecta permaneza vigente.
Los datos personales tratados por Boxer tendrán un tratamiento confidencial y limitado a la finalidad con la que son recabados, procurando en todo momento su seguridad física, controles de acceso, idoneidad y mantenimiento constante en las instalaciones, repositorios, medios físicos, ópticos o cualquier otro medio en los que sean almacenados.
Cualquier vulneración a los datos personales sujetos a la LFPDPPP o a los repositorios físicos o electrónicos en donde éstos sean almacenados por Boxer, serán notificados en su página de Internet, a través de medios masivos de comunicación y/o directo al titular de los Datos.
Los titulares de los Datos, como titulares, tienen derecho a (i) acceder a sus datos personales en posesión de Boxer y conocer los detalles del tratamiento de los mismos, (ii) rectificarlos en caso de estar desactualizados, ser inexactos o estar incompletos, (iii) cancelarlos cuando considere que no están siendo utilizados conforme a los principios, deberes y obligaciones aplicables, u (iv) oponerse al tratamiento de los mismo para fines específicos. Estos derechos se conocen como los Derechos ARCO.
Para el ejercicio de sus Derechos ARCO por favor envíe la solicitud al correo electrónico email@example.com. La solicitud deberá contener la siguiente información y documentación:
Nombre y copia de identificación oficial vigente del titular y/o su representante legal. En el caso del representante legal se deberá acompañar del documento con el que se acredite su personalidad. Los documentos deberán ser escaneados y adjuntados al correo electrónico para verificar su veracidad.
La descripción clara y precisa de los datos personales respecto de los cuales se busca ejercer los Derechos ARCO, así como el derecho o derechos que se desea ejercer, lo cual podrá hacerse en el texto del correo electrónico o en un documento adjunto escaneado. Dicho documento deberá estar debidamente firmado al final del mismo y rubricado al calce de cada una de las hojas.
Señalar expresamente el deseo de recibir la contestación de Boxer a su petición a través del correo electrónico que usted nos proporcione.
Cualquier otro elemento o documento digitalizado que facilite la localización de los datos personales.
En el caso de solicitudes de rectificación de datos personales, el titular de los datos deberá indicar, además de lo señalado anteriormente, las modificaciones a realizarse y aportar la documentación que sustente su petición.
Tratándose de solicitudes de acceso a datos personales, procederá la entrega previa acreditación de la identidad del solicitante o representante legal, según corresponda.
Boxer emitirá la respectiva contestación y se tramitará la solicitud en los plazos establecidos por la LFPDPPP. En los casos de solicitudes de cancelación u oposición de datos personales, Boxer de procederá al bloqueo y supresión de los datos, no obstante los conservará exclusivamente para efectos de las responsabilidades nacidas del nuevo tratamiento.
Boxer se reserva el derecho de efectuar modificaciones o actualizaciones a los términos y condiciones del presente Aviso, para la atención de cambios legislativos, políticas internas, nuevos requerimientos para la prestación u ofrecimiento de servicios y prácticas del mercado.
Dichas modificaciones estarán disponibles para los titulares de los datos a través de su página de Internet. En el Aviso se incluirá la fecha de la última actualización del mismo.
Al proporcionar sus datos personales, usted otorga su consentimiento para que éstos sean tratados en los términos de este Aviso y con estricto apego al mismo, a la LFPDPPP, su Reglamento y a las disposiciones aplicables.
La fecha de la última actualización al presente aviso de privacidad: 19 de mayo de 2021.